Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level <i>MET</i> amplification (<i>MET</i>amp) detected by liquid biopsy (LBx).
Xiuning Le(The University of Texas MD Anderson Cancer Center), Paul K. Paik(Memorial Sloan Kettering Cancer Center), Christopher Stroh(Universität Hamburg), Gordon Otto(Merck KGaA, Darmstadt (Germany)), Santiago Viteri(Instituto Oncológico Dr. Rosell), Carlos Cabrera Galvez(Hospital Universitari Sagrat Cor), Jin‐Hyoung Kang(The Catholic University of Korea Seoul St. Mary's Hospital), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Dilafruz Juraeva(Merck KGaA, Darmstadt (Germany)), Rolf Bruns(Inserm), Jan P. van Meerbeeck(Antwerp University Hospital), Young‐Chul Kim(Chonnam National University Hwasun Hospital), David Vicente Baz(Hospital Universitario Virgen Macarena), Andreas Johne(Merck KGaA, Darmstadt (Germany))
Cited by 13
Related Papers
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k